BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28574302)

  • 41. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
    Tsimberidou AM; Kantarjian HM; Estey E; Cortes JE; Verstovsek S; Faderl S; Thomas DA; Garcia-Manero G; Ferrajoli A; Manning JT; Keating MJ; Albitar M; O'Brien S; Giles FJ
    Leukemia; 2003 Jun; 17(6):1100-3. PubMed ID: 12764375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1.
    Bourlon C; Lipton JH; Deotare U; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Thyagu S; Messner HA; Michelis FV
    Eur J Haematol; 2017 Sep; 99(3):234-239. PubMed ID: 28556258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Central nervous system involvement by myeloid sarcoma: a report of 12 cases and review of the literature.
    Olar A; Lapadat R; Davidson CJ; Stein TD; Dahiya S; Perry A; Gheorghe G
    Clin Neuropathol; 2016; 35(5):314-25. PubMed ID: 27125868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
    Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
    Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.
    Abbas HA; Reville PK; Geppner A; Rausch CR; Pemmaraju N; Ohanian M; Sasaki K; Borthakur G; Daver N; DiNardo C; Bueso-Ramos C; Pierce S; Jabbour E; Garcia-Manero G; Konopleva M; Ravandi F; Kantarjian H; Kadia TM
    Leuk Lymphoma; 2021 Dec; 62(14):3402-3410. PubMed ID: 34380367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia.
    Ullman DI; Dorn D; Jones JA; Fasciano D; Ping Z; Kanakis C; Koenig RG; Salzman D; Peker D
    Histopathology; 2019 Aug; 75(2):185-192. PubMed ID: 30916362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
    Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
    Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.
    Movassaghian M; Brunner AM; Blonquist TM; Sadrzadeh H; Bhatia A; Perry AM; Attar EC; Amrein PC; Ballen KK; Neuberg DS; Fathi AT
    Leuk Lymphoma; 2015 Jun; 56(6):1698-703. PubMed ID: 25213180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. De novo myeloid sarcoma in a 4-month-old infant: a case report and review of the literature.
    Bain EE; Rothman I; Lin L
    J Cutan Pathol; 2013 Mar; 40(3):321-5. PubMed ID: 23095217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Granulocytic sarcoma of the spine: MRI and clinical review.
    Seok JH; Park J; Kim SK; Choi JE; Kim CC
    AJR Am J Roentgenol; 2010 Feb; 194(2):485-9. PubMed ID: 20093613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML).
    Lamy T; Goasguen JE; Mordelet E; Grulois I; Dauriac C; Drenou B; Chaperon J; Fauchet R; le Prise PY
    Leukemia; 1994 Nov; 8(11):1879-83. PubMed ID: 7526090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cutaneous myeloid sarcoma: natural history and biology of an uncommon manifestation of acute myeloid leukemia.
    Hurley MY; Ghahramani GK; Frisch S; Armbrecht ES; Lind AC; Nguyen TT; Hassan A; Kreisel FH; Frater JL
    Acta Derm Venereol; 2013 May; 93(3):319-24. PubMed ID: 23165700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Granulocytic sarcoma: a clinical and pathologic analysis of ten cases].
    Hou ZB; Shi HY; Liang X; Wang XM
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):331-4. PubMed ID: 22883673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Granulocytic sarcoma of the femur in a patient with acute megakaryoblastic leukaemia].
    Čolović N; Bogdanović A; Vidović A; Perunčić-Jovanović M; Čolović M
    Srp Arh Celok Lek; 2011; 139(11-12):805-8. PubMed ID: 22338480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Granulocytic sarcoma of pediatric head and neck: an institutional experience.
    Roby BB; Drehner D; Sidman JD
    Int J Pediatr Otorhinolaryngol; 2013 Aug; 77(8):1364-6. PubMed ID: 23810551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and pathologic analysis of extramedullary tumors after hematopoietic stem cell transplantation.
    Huang Q; Reddi D; Chu P; Snyder DS; Weisenburger DD
    Hum Pathol; 2014 Dec; 45(12):2404-10. PubMed ID: 25294373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.